PRECLINICAL PUBLICATION · 2020

The LipoxinA4 receptor agonist BML-111 ameliorates intestinal disruption following acute pancreatitis through the Nrf2-regulated antioxidant pathway.

Mouse / Chemical/toxin

Evidence by therapy association

Study details and outcomes are extracted in the context of a specific intervention. Separate associations are retained rather than silently merged.

BML-111

PMID 33383086 ↗2020Reported benefit

The LipoxinA4 receptor agonist BML-111 ameliorates intestinal disruption following acute pancreatitis through the Nrf2-regulated antioxidant pathway.

MouseChemical/toxin

Model: Acute pancreatitis with associated intestinal epithelial disruption

BML-111 increased E-cadherin, reduced apoptosis and reactive oxygen species and lessened pancreatic and intestinal injury, and these protective effects were abolished in Nrf2 deficient cells and Nrf2 knockout mice.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.